title: Chemotherapy in patients with recurrent and progressive central neurocytoma.
abstract: BACKGROUND
  Recurrent central neurocytoma is very rare and to the authors' knowledge data regarding its response to chemotherapy currently are not available.
  
  
  METHODS
  Three patients with progressive neurocytoma received chemotherapy after their informed consent was obtained. Disease recurred in two patients after surgery and radiotherapy and in one patient after surgery. The treatment regimen was comprised of etoposide, 40 mg/m(2)/day, for 4 days; cisplatin, 25 mg/m(2)/day, for 4 days; and cyclophosphamide, 1,000 mg/m(2), on Day 4; this cycle was repeated every 4 weeks.
  
  
  RESULTS
  Stabilization of disease was observed in 2 patients and complete remission was observed in 1 patient; at last follow-up, these responses had been maintained for 15 months, 18 months, and 36 months, respectively.
  
  
  CONCLUSIONS
  In this small series, this therapeutic regimen led to long term disease reduction, and merits further study.
authors.affiliation: Department of Medical Oncology, Azienda Ospedale-Università, Padova, Italy.
authors.forename: A A
authors.initials: AA
authors.lastname: Brandes
authors.forename: P
authors.initials: P
authors.lastname: Amistà
authors.forename: M
authors.initials: M
authors.lastname: Gardiman
authors.forename: L
authors.initials: L
authors.lastname: Volpin
authors.forename: D
authors.initials: D
authors.lastname: Danieli
authors.forename: B
authors.initials: B
authors.lastname: Guglielmi
authors.forename: C
authors.initials: C
authors.lastname: Carollo
authors.forename: G
authors.initials: G
authors.lastname: Pinna
authors.forename: S
authors.initials: S
authors.lastname: Turazzi
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D018306:Neurocytoma / Q000175:diagnosis / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003520:Cyclophosphamide; D002945:Cisplatin